( 10.1038/s41598-019-38956-2) [DOI] [PMC free article] [PubMed] [Google Scholar] 78.Steinberg WM, Buse JB, Ghorbani MLM, rsted DD, Nauck MA.LEADER Steering Committee & LEADER Trial Investigators
JAMA Cardiol 2(12):13151321 Arnold SV, Stone GW, Mack MJ, Chhatriwalla AK, Austin BA, Zhang Z et al (2020) Health status changes and outcomes in patients with heart failure and mitral regurgitation: COAPT Trial
What are the details, background, design and limitations of the study
Regulatory agencies, including the US Food and Drug Administration, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency, require extensive Phase III clinical trials, immunogenicity assessments, and comprehensive Chemistry, Manufacturing, and Controls data before approving new GLP-1 therapies or label expansions
Kaiser Permanente in California dropped coverage for patients with a BMI under 40 when prescribed for weight loss alone
These examples underscore the potential for GLP-1 RAs to address a wider range of health challenges in the future